Original articleIn silico prediction of brain and CSF permeation of small molecules using PLS regression models
Graphical abstract
Introduction
There is an increasing interest in predicting the process of passive translocation of drugs from the blood stream to the brain, in particular for pharmaceutical companies focusing on the development of drugs that act on targets in the central nervous system (CNS). The pharmacological activity of such CNS medicines not only depends on receptor affinity but also on the achieved compound concentration in brain. In many instances, however, access of chemicals to the brain is restricted at the level of the brain capillary endothelial wall that forms the blood–brain barrier (BBB). Direct measurements of BBB permeability or brain uptake of drugs is difficult and time-consuming and requires sophisticated in vitro experimental systems or animal experiments. Some examples of used techniques include in vitro models of the BBB [1], [2], in vivo pharmacokinetic and tissue distribution studies [3], [4] or in situ brain perfusion and capillary depletion experiments [5], [6]. In a clinical setting, access to brain tissue is not possible. It has therefore been suggested to use cerebrospinal fluid (CSF) as a surrogate marker for drug concentrations in brain tissue since this CNS compartment is accessible by lumbar puncture in human or ventricular puncture in experimental animals [7]. All mentioned techniques can be applied to detailed mechanistic studies with selected test compounds, however, their use for routine drug screening is not possible due to their limited throughput. This situation has created an interest in predictive in silico permeability models, which can be used to analyze compound libraries in an industrial setting and to guide medicinal chemists in drug discovery and development [8], [9], [10], [11].
It was the aim of the present study to develop and validate a computational blood–brain barrier permeation model, which can be used to predict the extent of passive uptake of drug-like organic molecules into brain tissue as well as CSF. We could thereby make use of a proprietary in-house database, which contains brain permeation data for 77 drug-like molecules and CSF exposure data for a subset of 37 molecules. All compounds were CNS active, derived from several structurally unrelated chemical series and were assumed not to be substrates of drug transporting proteins such as P-glycoprotein [12]. It was not possible to describe the dataset with existing brain permeation models, such as the quantitative structure–activity relationship (QSAR) model by Clark [13]. This as well as our interest in CNS permeation of drugs led to the development of a new and improved partial least square (PLS) regression model.
Section snippets
In vivo dataset
The proprietary in-house dataset in this study consists of CNS active compounds. These drug-like compounds are from different chemical classes covering a broad range of physicochemical and structural properties (Table 1). In the beginning, 91 compounds with reported brain to plasma ratios (BPR) were analyzed and a subset of 77 high-quality data was selected for this study (Table 2). Exclusion criteria were, for example, a poor aqueous solubility of the tested compounds (below 1 μg/mL),
Results and discussion
The distribution of molecules between the blood compartment and the central nervous system (CNS) is a complex process, which is the consequence of active and passive transport across two cellular barriers in the CNS. These are the blood–brain barrier (BBB), located at the endothelial cells of the brain vasculature, and the blood–liquor barrier (choroid plexus) [23]. One of the distinguishing properties of these barriers is the presence of high-resistance tight junctions, which seal the
Acknowledgements
We thank Dr. Sonia Poli and Dr. Philippe Coassolo for their advice and support. For the determination of distribution coefficients and solubility values we would like to thank Pia Warga, Virginie Micallef and Isabelle Parrilla.
References (33)
- et al.
Adv. Drug Deliv. Rev.
(2004) Drug Discov. Today
(2003)- et al.
J. Pharm. Sci.
(2003) J. Pharm. Sci.
(1999)- et al.
Brain Res. Bull.
(1996) - et al.
J. Pharm. Biomed. Anal.
(1996) - et al.
J. Pharm. Biomed. Anal.
(1994) - et al.
J. Pharm. Sci.
(1995) Adv. Drug Deliv. Rev.
(1995)- et al.
J. Pharm. Sci.
(1995)
Cell. Mol. Neurobiol.
Exp. Brain Res.
Bioorg. Med. Chem. Lett.
J. Pharmacol. Exp. Ther.
J. Neurochem.
J. Drug Target.
Cited by (43)
Modeling ADMET properties based on biomimetic chromatographic data
2023, Cheminformatics, QSAR and Machine Learning Applications for Novel Drug DevelopmentIn vitro blood brain barrier models: An overview
2022, Journal of Controlled ReleaseCitation Excerpt :As a result, it is crucial to the predictive power of estimations that the dataset selection process is correct. Passive diffusion as the major route of transport over the BBB is assumed when in silico predictions omit other BBB transport pathways, such as nanoparticle- or carrier-mediated transport, receptor-mediated transport and active efflux or influx transport [130]. Advanced strategies have been established to enhance the prediction capacity of these computer models.
In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain
2018, Journal of Controlled ReleaseCitation Excerpt :This method takes the advantage of currently available data on molecules with known logBB and subsequently models the correlation between logBB and molecular properties of the target molecules. Different molecular properties, known as molecular descriptors, such as molecular volume, solvent accessible surface area (SASA), polarity, hydrogen bond acidity and hydrogen bond basicity, polarizability, lipophilicity, solvation energy and octanol/water partition coefficient have been used in QSAR modeling [325,327–339]. Training of the model with a dataset is the basis of the QSAR technique, therefore both the quality and quantity of the training dataset are important.
Combined computational-experimental approach to predict blood–brain barrier (BBB) permeation based on “green” salting-out thin layer chromatography supported by simple molecular descriptors
2017, Journal of Pharmaceutical and Biomedical AnalysisDiscovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists
2013, Bioorganic and Medicinal Chemistry LettersHighly potent and selective cannabinoid receptor 2 agonists: Initial hit optimization of an adamantyl hit series identified from high-through-put screening
2013, Bioorganic and Medicinal Chemistry Letters